RIGEL PHARMACEUTICALS INC
RIGEL PHARMACEUTICALS INC (RIGL): 9 pipeline candidates · 3 upcoming catalysts · ~12 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
11.8 months
D/E 0.26
Lead: Approved
9 candidates
3 upcoming, next in ~2231d
0 buys · 2 sells (180d)
A transparent, data-derived signal for RIGEL PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$601.1M
Cash
$24.5M
Quarterly Burn
$42.3M
Runway
11.8 mo
Revenue
$58.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| cyp1a2 | Phase 4 |
| gavreto | Approved |
| ocadusertib | Phase 2 |
| olutasidenib + tmz | Phase 4 |
| r289 | Phase 1/Phase 2 |
| r552 | Phase 2 |
| r906289 mono | Phase 1/Phase 2 |
| rezlidhia | Approved |
| tavalisse | Approved |
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
148
Total value held
$423.0M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 1,768,907 | $47.8M |
| vanguard capital management llc | 1,528,386 | $41.3M |
| armistice capital, llc | 1,280,000 | $34.6M |
| state street corp | 1,120,238 | $30.3M |
| marshall wace, llp | 598,378 | $16.2M |
| american century companies inc | 544,431 | $14.7M |
| d. e. shaw & co., inc. | 445,678 | $12.1M |
| geode capital management, llc | 440,626 | $11.9M |
| goldman sachs group inc | 439,101 | $11.9M |
| two sigma investments, lp | 405,807 | $11.0M |
Showing top 10 of 148 institutional holders of RIGEL PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in RIGEL PHARMACEUTICALS INC's pipeline?
RIGEL PHARMACEUTICALS INC (RIGL) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RIGEL PHARMACEUTICALS INC's lead drug candidate?
RIGEL PHARMACEUTICALS INC's most advanced tracked candidate is cyp1a2 (Phase 4) for AML (Acute Myeloid Leukemia).
What is RIGEL PHARMACEUTICALS INC's next catalyst?
RIGEL PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: TAVALISSE" — expected July 27, 2032.
What is RIGEL PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RIGEL PHARMACEUTICALS INC has approximately 11.8 months of cash runway.
What is RIGEL PHARMACEUTICALS INC's market capitalization?
RIGEL PHARMACEUTICALS INC's market capitalization is approximately $601.1M.
Get the full picture on RIGEL PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.